Tesamorelin research is unusual in this field: instead of a handful of small studies, there is a run of large randomised controlled trials, several published in major journals. This page summarises that literature in plain language, with links to every paper on PubMed. We supply tesamorelin for laboratory research only, so nothing here is a claim about effects in humans.
What is tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. Like the natural hormone, it acts on the pituitary to stimulate the release of growth hormone, which in turn raises IGF-1. A 2009 review in Expert Opinion on Investigational Drugs describes its development, and a 2015 population pharmacokinetic analysis in Clinical Pharmacokinetics characterises how it behaves in the body across healthy subjects and patients.
An important distinction
Tesamorelin is an approved prescription medicine in some countries for one specific clinical indication, prescribed and supervised by clinicians. The material we supply is not that medicine, is not a substitute for it, and is not for human use. The studies below are described because they are the published evidence base a researcher would want to know about, not as guidance for anyone considering the licensed product. That is a conversation for a doctor.
Tesamorelin research: what the trials show
Nearly all of the human work in the tesamorelin research base has been conducted in one clinical population, in people with HIV who have accumulated visceral abdominal fat. Three strands run through it: body composition, liver fat, and a separate line of work on cognition. All papers are linked in the reference list.
Body composition trials
A 2005 dose-ranging trial in AIDS established the groundwork. The pivotal results appeared in a 2007 multicentre randomised trial in the New England Journal of Medicine, followed by a 2010 randomised placebo-controlled trial in JAIDS and a 2008 study in AIDS examining longer-term safety and effects. A 2012 phase III analysis in Clinical Infectious Diseases reported that reductions in visceral fat tracked with an improved metabolic profile. More recently, a 2024 randomised trial in AIDS examined efficacy and safety in people taking integrase inhibitors, and two 2026 meta-analyses have pooled the randomised evidence.
Liver fat
A 2014 randomised clinical trial in JAMA measured effects on both visceral fat and liver fat. A 2019 randomised, double-blind multicentre trial in Lancet HIV then looked specifically at non-alcoholic fatty liver disease. Mechanistic follow-ups examined hepatic transcriptomic signatures in JCI Insight in 2020 and response pathways in Scientific Reports in 2021, while a 2021 study in AIDS reported changes in fat quality independent of changes in fat quantity.
Cognition studies
A separate line of research used GHRH administration rather than treating body composition. A 2012 controlled trial in Archives of Neurology examined cognitive function in adults with mild cognitive impairment and in healthy older adults. Related work reported effects on brain GABA levels in JAMA Neurology in 2013 and on neuronal exosome biomarkers in the Journal of Alzheimer’s Disease in 2018. These are small studies, and the findings have not been established in larger trials.
Limits of the current evidence
Tesamorelin research is strong for its size but narrow in scope. Almost all of it comes from one patient population studied for one indication, much of it sponsor-funded, so it says little about effects in anyone else. The cognition studies are small and early. As with any GHRH analogue, raising the GH/IGF-1 axis has metabolic consequences the trials monitored closely, and those trials were conducted under clinical supervision that has no equivalent outside a clinic.
Research use only
AurumLabs supplies tesamorelin strictly for laboratory research. It is not for human or animal use, and it is not a medicine or supplement. Our tesamorelin vials ship with a batch-specific Certificate of Analysis, and you can explore more summaries in our research library.
References
- A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS, 2005. PMID: 16052083
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med, 2007. PMID: 18057338
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 2008. PMID: 18690162
- Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial. J Acquir Immune Defic Syndr, 2010. PMID: 20101189
- Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis, 2012. PMID: 22495074
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014. PMID: 25038357
- Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet, 2015. PMID: 25358450
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 2019. PMID: 31611038
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 2020. PMID: 32701508
- Tesamorelin improves fat quality independent of changes in fat quantity. AIDS, 2021. PMID: 33756511
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 2024. PMID: 38905488
- Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol, 2012. PMID: 22869065
- Growth hormone-releasing hormone effects on brain GABA levels in mild cognitive impairment and healthy aging. JAMA Neurol, 2013. PMID: 23689947
- Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs, 2009. PMID: 19243281
